40
Participants
Start Date
May 1, 2019
Primary Completion Date
May 8, 2026
Study Completion Date
May 8, 2026
Questionnaire Administration
Ancillary studies
Radiation Therapy
Undergo RT
Telaglenastat Hydrochloride
Given PO
Temozolomide
Given PO
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Sibley Memorial Hospital, Washington D.C.
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
University of Virginia Cancer Center, Charlottesville
Moffitt Cancer Center, Tampa
University of Kentucky/Markey Cancer Center, Lexington
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Mayo Clinic in Rochester, Rochester
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
Siteman Cancer Center at Christian Hospital, St Louis
Siteman Cancer Center at West County Hospital, Creve Coeur
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
University of Oklahoma Health Sciences Center, Oklahoma City
M D Anderson Cancer Center, Houston
Huntsman Cancer Institute/University of Utah, Salt Lake City
Mayo Clinic Hospital in Arizona, Phoenix
Mayo Clinic in Arizona, Scottsdale
UC San Diego Moores Cancer Center, La Jolla
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Mayo Clinic in Florida, Jacksonville
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH